Neuropace (NPCE)

• Market cap: $357M
• 1 day: 0.50%
• 5 days: -0.25%
• 1 month: 3.91%
• 3 months: 87.32%
• 6 months: 59.39%
• Year to date: 3.37%
• 1 year: -7.92%
• 5 years: -52.04%
• 10 years: -52.04%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Employees: 184

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

800% more call options, than puts

Call options by funds: $9K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

6% less funds holding

Funds holding: 51 [Q2] → 48 (-3) [Q3]

10.2% less ownership

Funds ownership: 60.91% [Q2] → 50.71% (-10.2%) [Q3]

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

22% less capital invested

Capital invested by funds: $132M [Q2] → $103M (-$29.3M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 9% upside
• Avg. target: $13.50 13% upside
• High target: $14 17% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Robbie Marcus 62% 1-year accuracy 13 / 21 met price target	17% upside $14	Overweight Maintained	17 Dec 2024
Wells Fargo Vik Chopra 70% 1-year accuracy 7 / 10 met price target	9% upside $13	Overweight Maintained	13 Nov 2024